Our Director of Research Dr Sheona Scales describes her four highlights from this year's Clinical Trials on Alzheimer's ...
Alzheimer’s trials face the unique challenge of studying participants with cognitive decline, amid a move towards digital ...
The $74.5 million grant will fund a study focused on an inherited genetic mutation that has been linked to Alzheimer's.
A single course of newly approved Alzheimer's drug donanemab-azbt, the second medicine available in Japan targeting proteins in the brains of sufferers of the debilitating disease, will cost 3.08 ...
For the last eight years, Lakeland resident Natalie Aviles has participated in Walk to End Alzheimer’s Polk County. Each year ...
Anti-amyloid antibodies lecanemab and donanemab are in clinical use now, but that does not mean research on them has stopped. At the Clinical Trials on Alzheimer’s Disease conference, held October ...
Taking Out OGA. The rationale behind small-molecule OGA inhibition is that these drugs will decrease tau hyperphosphorylation ...
Hosted on MSN5d
Ozempic and Viagra, among the more than 80 drugs expected to work against Alzheimer's in the coming yearsToday, the first monoclonal antibodies, lecanemab and donanemab, are available, showing that their reduction effect on these ...
Donanemab became the second Alzheimer's drug that targets causative deposited plaque in the brain to win the coverage after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback